|
1
|
Sharma SV, Haber DA and Settleman J: Cell
line-based platforms to evaluate the therapeutic efficacy of
candidate anticancer agents. Nat Rev Cancer. 10:241–253. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Shamir ER and Ewald AJ: Three-dimensional
organotypic culture: Experimental models of mammalian biology and
disease. Nat Rev Mol Cell Biol. 15:647–664. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Arrowsmith J and Miller P: Trial watch:
Phase II and phase III attrition rates 2011–2012. Nat Rev Drug
Discov. 12:5692013. View
Article : Google Scholar : PubMed/NCBI
|
|
4
|
Arrowsmith J: Trial watch: Phase II
failures: 2008–2010. Nat Rev Drug Discov. 10:328–329. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
DiMasi JA, Reichert JM, Feldman L and
Malins A: Clinical approval success rates for investigational
cancer drugs. Clin Pharmacol Ther. 94:329–335. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Tentler JJ, Tan AC, Weekes CD, Jimeno A,
Leong S, Pitts TM, Arcaroli JJ, Messersmith WA and Eckhardt SG:
Patient-derived tumour xenografts as models for oncology drug
development. Nat Rev Clin Oncol. 9:338–350. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Siolas D and Hannon GJ: Patient-derived
tumor xenografts: Transforming clinical samples into mouse models.
Cancer Res. 73:5315–5319. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Rosfjord E, Lucas J, Li G and Gerber HP:
Advances in patient-derived tumor xenografts: From target
identification to predicting clinical response rates in oncology.
Biochem Pharmacol. 91:135–143. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Hidalgo M, Amant F, Biankin AV, Budinská
E, Byrne AT, Caldas C, Clarke RB, de Jong S, Jonkers J, Mælandsmo
GM, et al: Patient-derived xenograft models: An emerging platform
for translational cancer research. Cancer Discov. 4:998–1013. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Gao H, Korn JM, Ferretti S, Monahan JE,
Wang Y, Singh M, Zhang C, Schnell C, Yang G, Zhang Y, et al:
High-throughput screening using patient-derived tumor xenografts to
predict clinical trial drug response. Nat Med. 21:1318–1325. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Weeber F, Ooft SN, Dijkstra KK and Voest
EE: Tumor organoids as a pre-clinical cancer model for drug
discovery. Cell Chem Biol. 24:1092–1100. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Crespo M, Vilar E, Tsai SY, Chang K, Amin
S, Srinivasan T, Zhang T, Pipalia NH, Chen HJ, Witherspoon M, et
al: Colonic organoids derived from human induced pluripotent stem
cells for modeling colorectal cancer and drug testing. Nat Med.
23:878–884. 2017. View
Article : Google Scholar : PubMed/NCBI
|
|
13
|
Sato T, Stange DE, Ferrante M, Vries RG,
Van Es JH, Van den Brink S, Van Houdt WJ, Pronk A, Van Gorp J,
Siersema PD, et al: Long-term expansion of epithelial organoids
from human colon, adenoma, adenocarcinoma, and Barrett's
epithelium. Gastroenterology. 141:1762–1772. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
van de Wetering M, Francies HE, Francis
JM, Bounova G, Iorio F, Pronk A, van Houdt W, van Gorp J,
Taylor-Weiner A, Kester L, et al: Prospective derivation of a
living organoid biobank of colorectal cancer patients. Cell.
161:933–945. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Boj SF, Hwang CI, Baker LA, Chio II, Engle
DD, Corbo V, Jager M, Ponz-Sarvise M, Tiriac H, Spector MS, et al:
Organoid models of human and mouse ductal pancreatic cancer. Cell.
160:324–338. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Gao D, Vela I, Sboner A, Iaquinta PJ,
Karthaus WR, Gopalan A, Dowling C, Wanjala JN, Undvall EA, Arora
VK, et al: Organoid cultures derived from patients with advanced
prostate cancer. Cell. 159:176–187. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Girda E, Huang EC, Leiserowitz GS and
Smith LH: The use of endometrial cancer patient-derived organoid
culture for drug sensitivity testing is feasible. Int J Gynecol
Cancer. 27:1701–1707. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Broutier L, Mastrogiovanni G, Verstegen
MM, Francies HE, Gavarró LM, Bradshaw CR, Allen GE, Arnes-Benito R,
Sidorova O, Gaspersz MP, et al: Human primary liver cancer-derived
organoid cultures for disease modeling and drug screening. Nat Med.
23:1424–1435. 2017. View
Article : Google Scholar : PubMed/NCBI
|
|
19
|
Pauli C, Hopkins BD, Prandi D, Shaw R,
Fedrizzi T, Sboner A, Sailer V, Augello M, Puca L, Rosati R, et al:
Personalized in vitro and in vivo cancer models to guide precision
medicine. Cancer Discov. 7:462–477. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Kondo J, Endo H, Okuyama H, Ishikawa O,
Iishi H, Tsujii M, Ohue M and Inoue M: Retaining cell-cell contact
enables preparation and culture of spheroids composed of pure
primary cancer cells from colorectal cancer. Proc Natl Acad Sci
USA. 108:6235–6240. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Endo H, Okami J, Okuyama H, Kumagai T,
Uchida J, Kondo J, Takehara T, Nishizawa Y, Imamura F, Higashiyama
M, et al: Spheroid culture of primary lung cancer cells with
neuregulin 1/HER3 pathway activation. J Thorac Oncol. 8:131–139.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Kiyohara Y, Yoshino K, Kubota S, Okuyama
H, Endo H, Ueda Y, Kimura T, Kimura T, Kamiura S and Inoue M: Drug
screening and grouping by sensitivity with a panel of primary
cultured cancer spheroids derived from endometrial cancer. Cancer
Sci. 107:452–460. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Yoshida T, Okuyama H, Endo H and Inoue M:
Spheroid cultures of primary urothelial cancer cells: Cancer
tissue-originated spheroid (CTOS) method. Methods Mol Biol.
1655:145–153. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Miura A, Honma R, Togashi T, Yanagisawa Y,
Ito E, Imai J, Isogai T, Goshima N, Watanabe S and Nomura N:
Differential responses of normal human coronary artery endothelial
cells against multiple cytokines comparatively assessed by gene
expression profiles. FEBS Lett. 580:6871–6879. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Okabe N, Ezaki J, Yamaura T, Muto S, Osugi
J, Tamura H, Imai J, Ito E, Yanagisawa Y, Honma R, et al: FAM83B is
a novel biomarker for diagnosis and prognosis of lung squamous cell
carcinoma. Int J Oncol. 46:999–1006. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Higa A, Hoshi H, Yanagisawa Y, Ito E,
Morisawa G, Imai JI, Watanabe S and Takagi M: Evaluation system for
arrhythmogenic potential of drugs using human-induced pluripotent
stem cell-derived cardiomyocytes and gene expression analysis. J
Toxicol Sci. 42:755–761. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Ito M, Hiramatsu H, Kobayashi K, Suzue K,
Kawahata M, Hioki K, Ueyama Y, Koyanagi Y, Sugamura K, Tsuji K, et
al: NOD/SCID/gamma(c)(null) mouse: An excellent recipient mouse
model for engraftment of human cells. Blood. 100:3175–3182. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Chijiwa T, Kawai K, Noguchi A, Sato H,
Hayashi A, Cho H, Shiozawa M, Kishida T, Morinaga S, Yokose T, et
al: Establishment of patient-derived cancer xenografts in
immunodeficient NOG mice. Int J Oncol. 47:61–70. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Pearson AT, Finkel KA, Warner KA, Nör F,
Tice D, Martins MD, Jackson TL and Nör JE: Patient-derived
xenograft (PDX) tumors increase growth rate with time. Oncotarget.
7:7993–8005. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Zhang JH, Chung TD and Oldenburg KR: A
simple statistical parameter for use in evaluation and validation
of high throughput screening assays. J Biomol Screen. 4:67–73.
1999. View Article : Google Scholar : PubMed/NCBI
|
